p2i Enterprise Fair

(18th – 20th March 2020, PSL - Paris)

Are you a postdoc eager to find new career opportunities and to discover entrepreneurial success stories?

Whether or not you are engaged in a startup project, participate in the p2i Paris Enterprise fair, from 18 to 20 March 2020, to learn more about entrepreneurship, to accelerate your project and to develop your professional network by exchanging with researchers from all over Europe.

The p2i programmme includes hands-on training sessions and multiple exchange opportunities, to better understand the process of creating a startup. Experts and entrepreneurial researchers will help you familiarize with the tools and practices of innovation and entrepreneurship.

During this event, the speakers will share with you their competences in:

  • Creativity methods
  • Intellectual Property Strategy
  • Communication: pitch, verbal and non-verbal communication
  • Finance: financial plan, investors’ expectations
  • Market strategy: business model, market analysis

After participating in this event, you will be able to explore new professional horizons and get off the beaten track!

We look forward to receiving your application and meeting you soon,
This event will begin on Wednesday, March 18 at 4pm and will close on Friday, March 20 at 2pm.

limited number of places are available and attendance is by application only.

Travel, accommodation, registration and subsistence costs will be covered by the p2i network for postdocs/early career researchers from p2i partner institutions (**) travelling from outside of Cambridge.  Participants need to be available for travel on 18th and 20 th November (possibly 17th or 21st depending on flights/trains) 2020. 

Please complete application FORM HERE

The deadline for applications is Monday 14th February 2020, 12.00, Noon (UK time)
Successful applicants will be notified by 20th February.

** University of Cambridge, University of Glasgow, Paris Sciences et Lettres (PSL) Université Paris, Freie Universität Berlin, Universität Innsbruck, Schlumberger, BP, AstraZeneca,

This post is also available in: Englisch